Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Pontrelli, Giuseppe ^a   Cotugno, Nicola ^a   Amodio, Donato ^a   Zangari, Paola ^a   Tchidjou, Hyppolite K ^a   Baldassari, Stefania ^a   Palma, Paolo ^a   Bernardi, Stefania ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PHOSPHONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; LONG TERM CARE; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KIDNEY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; PHYSIOLOGY;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; CHILD; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES;

EID: 84856040669     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-18     Document Type: Article

References (33)

1. D'Arminio Monforte A, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arc Intern Med 2005, 165:416-423.
2. Chiappini E, Galli L, Tovo PA, et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS 2007, 21:1607-1615. 10.1097/QAD.0b013e32823ecf5b, 17630556.
3. Guideline on the clinical development of medical products for the treatment of HIV infection. , http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003399.pdf
4. Roling J, Schmid H, Fischereder M, et al. HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy. Clin Infect Dis 2006, 42:1488-1495. 10.1086/503566, 16619164.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2011, 1-166. Available at [http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf].
6. Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS 2003, 17:2543-2544. 10.1097/00002030-200311210-00021, 14600530.
7. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003, 17:935-937. 10.1097/00002030-200304110-00026, 12660548.
8. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, et al. Tenofovir related nephrotoxicity in HIV-infected patients. AIDS 2004, 18:960-963. 10.1097/00002030-200404090-00019, 15060449.
9. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006, 42:283-290. 10.1086/499048, 16355343.
10. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, et al. Drug induced Fanconi's syndrome. Am J Kidney Dis 2003, 41:292-309. 10.1053/ajkd.2003.50037, 12552490.
11. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008, 22:99-103. 10.1089/apc.2007.0052, 18260800.
12. Cirino CM, Kan VL. Hypokalemia in HIV patients on tenofovir. AIDS 2006, 20(12):1671-1673. 10.1097/01.aids.0000238416.05819.09, 16868451.
13. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005, 116(6):846-854.
14. Viganò A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig 2011, 31(6):407-415. 10.2165/11590400-000000000-00000, 21528939.
15. Hussain S, Khayat A, Tolaymat A. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006, 21:1034-1036. 10.1007/s00467-006-0109-3, 16773419.
16. Rollot F, Nazal E, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavirdidanosine. Clin Infect Dis 2003, 37:174-176.
17. Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010, 24(4):525-534. 10.1097/QAD.0b013e3283333680, 20139752.
18. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008, 152:582-584. 10.1016/j.jpeds.2007.12.020, 2390888, 18346519.
19. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 2009, 10(10):1675-1685. 10.2217/pgs.09.115, 19842939.
20. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008, 83(2):265-272. 10.1038/sj.clpt.6100269, 17597712.
21. Viread SUMMARY OF PRODUCT CHARACTERISTICS. European Medicines Agency Viread., http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000419/WC500051737.pdf pag.8
22. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Adolescent Trials Network for HIV/AIDS Interventions. Antimicrob Agents Chemother 2008, 52(2):631-637. 10.1128/AAC.00761-07, 2224775, 18025112.
23. Robertson EE, Ranking GO. Human renal organic anion transporters: characteristics and contributors to drug and drug metabolite excretion. Pharmacol Ther 2006, 109:383-389.
24. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009, 23:197-1975.
25. Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 2009, 10(6):329-336. 10.1111/j.1468-1293.2008.00691.x, 19226409.
26. Riordan A, Judd A, Boyd K, et al. Tenofovir use in Human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2009, 28:204-209. 10.1097/INF.0b013e31818c8d2c, 19209091.
27. Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006, 21(7):1034-1036. 10.1007/s00467-006-0109-3, 16773419.
28. Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 2011, 25(2):171-176. 10.1097/QAD.0b013e328340fdca, 21076275.
29. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009, 23(6):689-696. 10.1097/QAD.0b013e3283262a64, 19262355.
30. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008, 197:102-108. 10.1086/524061, 18171292.
31. Daar E, Tierney C, Fischl M, et al. ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIVinfected patients. [Abstract 59LB.]. 17th Conference on Retroviruses and Opportunistic Infections 2010, San Francisco, CA.
32. Kiser JJ, Aquilante CL, Anderson PL, et al. Effect of Multidrug resistance proteins 2 and 4 polymorphisms on tenofovir pharmacokinetics in HIV-infected patients. 7th International Workshop on Clinical Pharmacology of HIV Therapy 2006, Lisbon, Portugal.
33. Giacomet V, Mora S, Martelli L, et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 2005, 40:448-450. 10.1097/01.qai.0000184860.62189.c8, 16280700.